# Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma

Source: https://onco.cc/trials/nct06697301/  
OnCo record `nct06697301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing EIK1001 in melanoma, now recruiting.

## Summary

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma is a phase 2/3 interventional study registered as NCT06697301, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Randomised, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006). Planned enrolment is 740 participants (estimated). The study started in 2025-05-22 and primary completion is expected in 2035-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: TeLuRide-006
- Tags: ctgov-ingest
- Registry id: NCT06697301
- Phase: 2/3
- Setting: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
- Sponsor: Eikon Therapeutics
- Enrolled: 740

## Sources

- ClinicalTrials.gov NCT06697301: https://clinicaltrials.gov/study/NCT06697301

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [EIK1001](https://onco.cc/drugs/eik1001/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06697301.json